Heparin-induced thrombocytopenia and cardiovascular patients: recognition and treatment.
Baker
Kathy M
KM
Virginia Commonwealth University, Richmond, VA 23298, USA.
Flattery
Maureen P
MP
D000925:Anticoagulants / Q000009:adverse effects*; D001120:Arginine / Q000031:analogs & derivatives; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins / Q000494:pharmacology; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D010875:Pipecolic Acids / Q000494:pharmacology / Q000627:therapeutic use; D010978:Platelet Factor 4 / Q000187:drug effects / Q000276:immunology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control
D000925:Anticoagulants; D006629:Hirudins; D010446:Peptide Fragments; D010875:Pipecolic Acids; D011994:Recombinant Proteins; D013449:Sulfonamides; D010978:Platelet Factor 4; D006493:Heparin; D001120:Arginine; C031942:argatroban; C074619:bivalirudin; C083544:lepirudin